Phil Schwab

833 total citations
21 papers, 239 citations indexed

About

Phil Schwab is a scholar working on Endocrinology, Diabetes and Metabolism, Epidemiology and Family Practice. According to data from OpenAlex, Phil Schwab has authored 21 papers receiving a total of 239 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Epidemiology and 4 papers in Family Practice. Recurrent topics in Phil Schwab's work include Diabetes Treatment and Management (7 papers), Medication Adherence and Compliance (4 papers) and Diabetes Management and Research (4 papers). Phil Schwab is often cited by papers focused on Diabetes Treatment and Management (7 papers), Medication Adherence and Compliance (4 papers) and Diabetes Management and Research (4 papers). Phil Schwab collaborates with scholars based in United States and Belgium. Phil Schwab's co-authors include Chad Moretz, Andrew Renda, Srinivas Annavarapu, Amol D. Dhamane, Sari Hopson, Shuchita Kaila, Benjamin Hall, Kaan Tunceli, Boyang Bian and Insiya B. Poonawalla and has published in prestigious journals such as Diabetes, American Journal of Transplantation and Molecular Cancer Therapeutics.

In The Last Decade

Phil Schwab

19 papers receiving 229 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Phil Schwab United States 10 71 63 52 50 39 21 239
Felicité Kamdem Cameroon 11 25 0.4× 71 1.1× 72 1.4× 21 0.4× 23 0.6× 52 407
Mahmoud Hassanein Egypt 11 50 0.7× 129 2.0× 57 1.1× 28 0.6× 22 0.6× 29 532
Narendra C. Bhalodkar United States 9 37 0.5× 123 2.0× 65 1.3× 34 0.7× 19 0.5× 15 330
Rykel van Bruggen Netherlands 8 13 0.2× 120 1.9× 51 1.0× 42 0.8× 25 0.6× 16 302
Su Yan China 3 16 0.2× 70 1.1× 38 0.7× 39 0.8× 101 2.6× 4 401
Javier García Alegría Spain 12 20 0.3× 114 1.8× 47 0.9× 16 0.3× 18 0.5× 38 364
Olga Laszczyńska Portugal 11 23 0.3× 12 0.2× 42 0.8× 41 0.8× 21 0.5× 26 333
Anna Hung United States 10 24 0.3× 20 0.3× 30 0.6× 31 0.6× 55 1.4× 58 292
Chad Moretz United States 10 217 3.1× 61 1.0× 82 1.6× 32 0.6× 9 0.2× 27 334
C. Attali France 12 38 0.5× 140 2.2× 72 1.4× 12 0.2× 14 0.4× 29 338

Countries citing papers authored by Phil Schwab

Since Specialization
Citations

This map shows the geographic impact of Phil Schwab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phil Schwab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phil Schwab more than expected).

Fields of papers citing papers by Phil Schwab

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phil Schwab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phil Schwab. The network helps show where Phil Schwab may publish in the future.

Co-authorship network of co-authors of Phil Schwab

This figure shows the co-authorship network connecting the top 25 collaborators of Phil Schwab. A scholar is included among the top collaborators of Phil Schwab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phil Schwab. Phil Schwab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
La, Elizabeth M., et al.. (2024). Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Human Vaccines & Immunotherapeutics. 20(1). 2303796–2303796. 18 indexed citations
2.
Schwab, Phil, et al.. (2023). Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi. Journal of Managed Care & Specialty Pharmacy. 29(10). 1109–1118. 1 indexed citations
3.
Hu, Amy, et al.. (2023). HIV preexposure prophylaxis treatment patterns in a national health plan population. Journal of Managed Care & Specialty Pharmacy. 29(12). 1267–1274.
4.
Poonawalla, Insiya B., et al.. (2021). A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists. Diabetes Research and Clinical Practice. 175. 108800–108800. 17 indexed citations
5.
Poonawalla, Insiya B., et al.. (2020). 36-OR: Comparative Effectiveness of SGLT2 Inhibitors vs. GLP-1 Agonists. Diabetes. 69(Supplement_1).
6.
Bhattacharya, Rituparna, et al.. (2020). Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases. Journal of Managed Care & Specialty Pharmacy. 26(10). 1246–1256. 3 indexed citations
7.
Poonawalla, Insiya B., et al.. (2020). 1428-P: Cardiovascular Outcomes with Dulaglutide vs. Liraglutide. Diabetes. 69(Supplement_1). 1 indexed citations
8.
Hall, Benjamin, et al.. (2019). Comparison of Medication Therapy Management Services and Their Effects on Health Care Utilization and Medication Adherence. Journal of Managed Care & Specialty Pharmacy. 25(6). 688–695. 34 indexed citations
9.
Schwab, Phil, et al.. (2019). A Retrospective Database Study Comparing Diabetes-Related Medication Adherence and Health Outcomes for Mail-Order Versus Community Pharmacy. Journal of Managed Care & Specialty Pharmacy. 25(3). 332–340. 11 indexed citations
10.
11.
Joshi, Kruti, et al.. (2018). Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. Journal of Comparative Effectiveness Research. 7(8). 723–735. 9 indexed citations
12.
Schwab, Phil, Amol D. Dhamane, Sari Hopson, et al.. (2017). Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. International Journal of COPD. Volume 12. 735–744. 46 indexed citations
13.
Schwab, Phil, et al.. (2017). A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia. Journal of Managed Care & Specialty Pharmacy. 23(12). 1221–1226. 11 indexed citations
14.
Bailey, Robert A., Phil Schwab, Yihua Xu, Margaret K. Pasquale, & Andrew Renda. (2016). Glycemic Control Outcomes After Canagliflozin Initiation: Observations in a Medicare and Commercial Managed Care Population in Clinical Practice. Clinical Therapeutics. 38(9). 2046–2057.e2. 5 indexed citations
15.
Dhamane, Amol D., Phil Schwab, Sari Hopson, et al.. (2016). Association between adherence to medications for COPD and medications for other chronic conditions in COPD patients. International Journal of COPD. Volume 12. 115–122. 30 indexed citations
16.
Yu, Shengsheng, Phil Schwab, Boyang Bian, Larry Radican, & Kaan Tunceli. (2016). Use of Add-on Treatment to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A U.S. Database Study. Journal of Managed Care & Specialty Pharmacy. 22(3). 272–280. 18 indexed citations
17.
Harris, Jennifer B., et al.. (2015). Is response-guided therapy being applied in the clinical setting? The hepatitis C example.. PubMed. 8(1). 22–8. 2 indexed citations
18.
Schwab, Phil, et al.. (2015). Abstract B102: NSCLC observations combining medical charts and administrative claims data. Molecular Cancer Therapeutics. 14(12_Supplement_2). B102–B102. 1 indexed citations
19.
Schwab, Phil, Anthony Louder, Yong Li, Rajiv Mallick, & Harold Bays. (2014). Cholesterol Treatment Patterns and Cardiovascular Clinical Outcomes Associated with Colesevelam HCl and Ezetimibe. Drugs & Aging. 31(9). 683–694. 3 indexed citations
20.
Markmann, James F., et al.. (2008). Financial Issues Constraining the Use of Pancreata Recovered for Islet Transplantation: A White Paper. American Journal of Transplantation. 8(8). 1588–1592. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Felicité Kamdem Breakdown of academic impact, for papers by Mahmoud Hassanein Breakdown of academic impact, for papers by Narendra C. Bhalodkar Breakdown of academic impact, for papers by Rykel van Bruggen Breakdown of academic impact, for papers by Su Yan Breakdown of academic impact, for papers by Javier García Alegría Breakdown of academic impact, for papers by Olga Laszczyńska Breakdown of academic impact, for papers by Anna Hung Breakdown of academic impact, for papers by Chad Moretz Breakdown of academic impact, for papers by C. Attali
Rankless by CCL
2026